Secerna LLP, based in York, bolsters its chemistry and pharmaceutical team.
- Melvyn Ansell, a leading patent attorney, joins the firm.
- Ansell holds a PhD and master’s in chemistry from the University of Sussex.
- His expertise includes patent drafting, prosecution, and litigation.
- Ansell’s addition is expected to elevate client services significantly.
Secerna LLP, a prestigious intellectual property firm located in York, has taken a significant step towards strengthening its capabilities in the chemistry and pharmaceutical sectors by recruiting Melvyn Ansell, an experienced UK and European patent attorney. The firm is known for offering a comprehensive array of intellectual property services, enhanced by a dedicated team of skilled patent attorneys who strive to meet the diverse IP needs of their clients.
Melvyn Ansell, who holds both a PhD and a master’s degree in chemistry from the University of Sussex, is the latest addition to the team. He brings to Secerna LLP a wealth of experience garnered from previous roles at several distinguished IP firms, further reinforced by his qualification to represent clients in the Unified Patent Court. His proficiency in patent law is expected to greatly benefit Secerna’s clientele, particularly in areas such as patent drafting, prosecution, and litigation.
Charlotte Watkins, a partner at the firm, expressed her enthusiasm concerning Ansell’s appointment, stating, “We are thrilled to welcome Melvyn to our team. His experience and knowledge will be a significant asset to our chemistry & pharmaceutical practice. We are confident that his addition will further enhance our ability to deliver exceptional service to our clients.”
Sharing his thoughts, Melvyn Ansell remarked, “I am delighted to have joined the Secerna LLP team. The opportunity was an obvious choice for me, given Secerna’s esteemed reputation for delivering high-quality work in the industry.”
The inclusion of Melvyn Ansell is poised to significantly enhance Secerna LLP’s service offerings in the chemistry and pharmaceutical sectors.
